Solagran is a biotechnology company with a portfolio of higly effective, low side effect, natural pharmaceuticals that it obtains from gree tree foliage. Its patented technology enables the extraction of the live elements of trees in a way that both preserves and amplifies their biological activity. 
The Directors of Solagran Limited are pleased to announce that Ms Victoria Gorbacheva, the Business Development & Marketing Director of Berlin-Chemie/Menarini Pharma GmbH, part of the international Menarini Pharmaceutical group, is visiting Melbourne to further progress ongoing discussions in relation to the licencing, marketing and distribution of Ropren
The Directors are pleased to announce that Solagran Limited (ASX: SLA) has engaged the Bank of New York to establish a level one American Depository Receipt (ADR) Program.
Solagran Limited (ASX: SLA) - Russian Patent Authority Accepts H.pylori Patent Application - Mr Denis Kilroy, Executive Director; Solagran Limited (ASX: SLA) present the following audio webcast regarding "SLA - Russian Patent Authority Accepts H.pylori Patent Application - Mr Denis Kilroy, Executive Director". You may also download this audio webcast to your computer or portable audio player.
The Directors of Solagran Limited (ASX: SLA) are pleased to announce that the Russian Agency for Patents and Trademarks has accepted a patent application submitted by Solagran covering the use of Bioeffective(r) A in the treatment of Helicobacter pylori infection. If awarded, the priority date for this patent will be 26 December, 2007.
Australian Biotech Solagran Limited (ASX: SLA) today announced it had been awarded the world's first patents protecting the use of plant polyprenols in the treatment of conditions involving physical, psychological and neurological degeneration.
Australian Biotech Solagran Limited (ASX: SLA) announced at its AGM today that it was on track to commence commercial production of its drug Ropren in January 2008.
The Directors of Solagran Limited (ASX: SLA) are pleased to announce the achievement of two important milestones in the ongoing development of its Bioeffective-R production facilities in Tomsk.
The Directors of Solagran Limited are pleased to advise that the Annual General
Meeting of Solagran Limited has been re-scheduled for 11.00am on Friday 21
December, 2007 at the Boulevard Room, St Kilda Road Parkview Hotel, 562 St Kilda
Road, Melbourne.
Solagran Limited (ASX: SLA) - Conifer Green Needle Complex - Dr Vladimir Bespalov, Chief of Cancer Chemoprevention, NN Petrov Institute of Oncology, St Petersburg; Solagran Limited (ASX: SLA) present the following audio webcast regarding "Conifer Green Needle Complex". You may also download this audio webcast to your computer or portable audio player.
Bioeffectives to be Used to Treat Alzheimer's Patients and Alcoholics in Russia The Directors of Solagran Limited are pleased to release a letter received from Dr Nina Golovkina, the Head of the Department of Psychosomatics at the Skvortsova- Stepanova Psychiatric Hospital in St Petersburg, confirming the very positive results of trials conducted by that hospital
